tempol has been researched along with losartan in 2 studies
| Studies (tempol) | Trials (tempol) | Recent Studies (post-2010) (tempol) | Studies (losartan) | Trials (losartan) | Recent Studies (post-2010) (losartan) |
|---|---|---|---|---|---|
| 19 | 0 | 15 | 7,231 | 1,245 | 2,118 |
| Protein | Taxonomy | tempol (IC50) | losartan (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 9.01 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.882 | |
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.019 | |
| Atrial natriuretic peptide receptor 3 | Homo sapiens (human) | 0.0018 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.019 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0247 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0234 | |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | 0.0032 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.047 | |
| Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | 0.025 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0118 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.019 | |
| Platelet glycoprotein VI | Homo sapiens (human) | 4 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.1481 | |
| Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.2884 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, J; Chen, Z; Cheng, Z; Hu, G; Jiang, D; Li, Q; Lu, M; Peng, Z; Tao, L; Xiong, X | 1 |
2 other study(ies) available for tempol and losartan
| Article | Year |
|---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Discovery; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Mice; Molecular Structure; NIH 3T3 Cells; Oxidative Stress; Piperazines; Pyridones; Rats; Structure-Activity Relationship | 2018 |